The bactericidal activity of gemifloxacin (SB-265805).

  title={The bactericidal activity of gemifloxacin (SB-265805).},
  author={Ian Morrissey and Skye Clark and I Mathias},
  journal={Journal of medical microbiology},
  volume={49 9},
The bactericidal activity and mechanisms of action of the new fluoroquinolone gemifloxacin were investigated against the laboratory strains Escherichia coli KL16, Staphylococcus aureus E3T and Streptococcus pneumoniae C3LN4. Gemifloxacin was found to be highly bactericidal against these bacteria, producing a biphasic dose-response curve typical of the fluoroquinolones. This novel fluoroquinolone was more bactericidal than all other fluoroquinolones so far tested (ciprofloxacin, ofloxacin… 
Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.
Findings indicate that the potent in vitro activity of gemifloxacin against S. pneumoniae, including ciprofloxacIn-resistant strains, results from a strong affinity for pneumococcal topoisomerase IV.
Advances in DNA gyrase inhibitors
The recent discovery of non-fluoroquinolones and 2-pyridone antibacterials represents yet additional progress in the search for novel DNA gyrase inhibitors.
Role of gemifloxacin in community-acquired pneumonia
  • G. Tillotson
  • Medicine
    Expert review of anti-infective therapy
  • 2008
Gemifloxacin administered for 5–7 days is a cost effective and safe alternative to both parenteral and oral antimicrobials, which may not cover the emerging resistant respiratory pathogens.
Chapter 4 – Gemifloxacin
A comprehensive profile on Gemifloxacin, a novel fluoroquinolone synthetic broad-spectrum antibacterial agent for oral administration, particularly indicated for treatment of community-acquired
Evaluation of synergistic antimicrobial activity of Gemifloxacin with Linum usitatissimum seed oil
It was concluded that linseed oil synergies the antimicrobial potential of gemifloxacin when used simultaneously in various combinations.
Expression of lux Genes in a Clinical Isolate of Streptococcus pneumoniae: Using Bioluminescence To Monitor Gemifloxacin Activity
A clinical isolate of Streptococcus pneumoniae was transformed with a plasmid containing the lux operon of Photorhabdus luminescens that had been modified to function in gram-positive bacteria that provided a sensitive, real-time measure of the pharmacodynamics of the fluoroquinolone gemifloxacin.
Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety.
Ciprofloxacin derivatives, containing a N-(chloro-substituted phenethyl) residue, showed in vitro Gram-positive and Gram-negative activity generally comparable or superior to that of reference quinolones.
Comparative Pharmacokinetics and Bioavailability of Gemifloxacin Administered as an Intravenous 200 mg Formulation or an Oral 320 mg Tablet
The clinical potential of a new gemifloxacin 200 mg intravenous formulation is assessed by comparing its pharmacokinetic characteristics with those of the branded Factive gem ifloxAcin tablet by using a validated high-performance liquid chromatography‐tandem mass spectrometry method.
Comparative Pharmacokinetics and Bioavailability of Gemifloxacin Administered as an Intravenous 200 mg Formulation or an Oral 320 mg Tablet
Intravenous 200 mg and oral 320 mg formulations of gemifloxacin are equivalent in terms of AUC following a single dose in healthy male subjects.
Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
Gemifloxacin is a new quinolone antibiotic that targets pneumococcal DNA gyrase and topoisomerase IV and is highly active against S. influenzae and the atypical pathogens, and has been shown to be as effective a range of comparators and demonstrated an adverse event profile that was in line with the comparator agents.